1,176 results match your criteria: "Nagano Red Cross Hospital; T. Fujibayashi[Affiliation]"

Article Synopsis
  • The prognostic nutritional index (PNI) is calculated using blood levels of lymphocytes and albumin and helps predict outcomes in patients with hepatocellular carcinoma (HCC) treated with specific drugs (atezolizumab plus bevacizumab).
  • A study involving 871 HCC patients showed that a PNI score of 41 can distinguish between low and high PNI groups, with high PNI linked to significantly longer overall survival (OS) and progression-free survival (PFS).
  • High PNI patients exhibited better disease control rates compared to low PNI patients, confirming that PNI is an important independent factor for predicting treatment success in HCC.
View Article and Find Full Text PDF

Rapid progression of left ventricular hypertrophy caused by leukaemic infiltration of myocardium.

Eur Heart J Cardiovasc Imaging

March 2023

Biomedical Imaging Laboratory, Graduate School of Biomedical Engineering, Tohoku University, 6-6-05 Aramaki Aza Aoba, Aobaku, Sendai 980-8579, Japan.

View Article and Find Full Text PDF

Background: Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first-line treatment for advanced non-small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C-reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil-to-lymphocyte ratio (C-PLAN) are useful biomarkers for predicting the prognosis of NSCLC; however, there are no reports examining the C-PLAN index, which combines these five factors in a single prognostic factor.

View Article and Find Full Text PDF

Nucleophosmin1 (NPM1) mutations are the most frequently detected gene mutations in acute myeloid leukemia (AML) and are considered a favorable prognostic factor. We retrospectively analyzed the prognosis of 605 Japanese patients with de novo AML, including 174 patients with NPM1-mutated AML. Although patients with NPM1-mutated AML showed a high remission rate, this was not a favorable prognostic factor for overall survival (OS); this is contrary to generally accepted guidelines.

View Article and Find Full Text PDF

Background: Bone marrow (BM) fibrosis is a condition characterized by deposition of reticulin and collagen fibers in BM. It may confer a poor prognosis in some of hematological malignancies. However, the relationship between fibrosis and the disease pathology is not fully understood and no biomarkers for BM fibrosis are available in clinical practice.

View Article and Find Full Text PDF

This study presents a new idea for estimating the number of measurements required for determining the uncertainty in obtaining the desired water absorbed dose using the variation obtained from multicenter absorbed dose measurement data. The number of dose measurements depends on the performance of each linear accelerator (LINAC) tested and the dosimetry equipment and procedure used. However, optimising the number of data collected for the absorbed dose to water has been inadequately reported.

View Article and Find Full Text PDF

Introduction: Accessory spleen torsion is extremely rare, and surgery is often the emergency or elective treatment of choice.

Presentation Of Case: A 20-year-old female with no specific medical history presented to our outpatient clinic with a chief complaint of abdominal pain. The patient was diagnosed with accessory spleen torsion by computed tomography.

View Article and Find Full Text PDF

Angioedema is a rare but potentially lethal side effect of angiotensin-converting enzyme inhibitors (ACEIs). Most ACEI-induced angioedema (ACEI-AE) cases have been reported in adults, with few reports of cases in children. Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder that presents with acute onset of symptoms, including headache, vomiting, visual disturbances, and seizures.

View Article and Find Full Text PDF

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.

Eur J Cancer

February 2023

Department of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - Univeristy of Bologna, Bologna, Italy.

Article Synopsis
  • A retrospective multi-centre study compared the effectiveness and safety of two treatment regimens—lenvatinib and atezolizumab plus bevacizumab—for patients with unresectable hepatocellular carcinoma (HCC).
  • The analysis involved 1341 patients on lenvatinib and 864 on the combination therapy, with overall survival (OS) as the main measure, showing no significant survival advantage for either treatment overall.
  • However, the results suggested that patients with viral liver disease might benefit more from the combination therapy, while those with non-alcoholic fatty liver disease could have better outcomes with lenvatinib, alongside a generally better safety profile for the combination treatment.
View Article and Find Full Text PDF

Aim: To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev).

Methods: A total of 286 patients with unresectable HCC treated with Atez/Bev as first-line systematic therapy were included.

Results: Regarding treatment-related AEs, decreased appetite of any grade, proteinuria of any grade, and fatigue of any grade were found with a frequency of ≥20%.

View Article and Find Full Text PDF

Introduction: Haemophilia B patients with factor IX inhibitors have particularly unmet needs for conventional therapy.

Aim: Phase II/III clinical trial, multicentre, open-label, prospective, self-controlled study was conducted to assess MC710 prophylaxis in haemophilia B patients with inhibitors.

Methods: We enrolled haemophilia patients who had received episodic or prophylactic treatment with bypassing agents up to that time.

View Article and Find Full Text PDF

Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting.

Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea).

Results: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab.

View Article and Find Full Text PDF

We conducted a cross-sectional study using a questionnaire to explore the late effects in survivors of allogenic hematopoietic stem cell transplantation (HSCT) for juvenile myelomonocytic leukemia (JMML). The attending pediatric hematologists/oncologists completed the questionnaires. Of the 30 survivors, approximately 83% showed more than one late effect.

View Article and Find Full Text PDF
Article Synopsis
  • The neo-Glasgow prognostic score (GPS) is a new biomarker developed to assess outcomes in hepatocellular carcinoma (HCC) patients undergoing liver surgery, and this study aimed to see if it could also predict outcomes for patients treated with atezolizumab and bevacizumab (Atez/Bev).
  • An analysis of 421 HCC patients revealed that both the GPS and the neo-GPS scores were independently associated with overall survival, with higher scores indicating worse survival rates.
  • The study concluded that the neo-GPS is an effective prognostic tool for evaluating advanced, unresectable HCC patients undergoing Atez/Bev treatment, offering stronger predictive power compared to the original GPS.
View Article and Find Full Text PDF
Article Synopsis
  • Schnitzler syndrome is a rare disorder characterized by chronic urticaria, and a nationwide survey in Japan revealed 36 clinically diagnosed cases from 1994 to 2022.
  • The median age of onset was 56.5 years, and it took an average of 3.3 years for patients to receive a final diagnosis after experiencing initial symptoms.
  • Treatments like high doses of corticosteroids were effective, with some patients also responding to agents like colchicine and IL-1 targeting therapies, but continued monitoring and research are necessary for better understanding and management of the disease.
View Article and Find Full Text PDF

Introduction: This study investigated the relationship between nutritional status, as determined by the prognostic nutritional index (PNI), and outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/bev).

Methods: The study analyzed 485 HCC patients treated with Atez/bev.

Results: There were 342 patients with a low PNI (<47) and 143 patients with a high PNI (≥47).

View Article and Find Full Text PDF

Background: Bulimia nervosa (BN) and the binge-eating/purging subtype of anorexia nervosa (b/p AN) are characterized by binge eating and unsafe compensatory behaviors, such as laxatives or diuretic abuse, self-induced vomiting, and excessive exercise. BN often causes miscellaneous physical complications that can lead to death. However, there have been very few prior reports on the physical complications of chronic BN.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness of cell-free and concentrated ascites reinfusion therapy (CART) and large-volume paracentesis (LVP) with albumin infusion in treating refractory ascites (RA) in patients with cirrhosis.
  • From June 2018 to March 2022, 25 patients were monitored for treatment outcomes, focusing on the number of paracenteses, drainage volume, and albumin use over 8 weeks.
  • Results showed that while CART required fewer paracenteses and albumin infusions, there were no significant differences in overall treatment effectiveness, suggesting both therapies are equally beneficial for managing RA.
View Article and Find Full Text PDF
Article Synopsis
  • The Japan Society of Obstetrics and Gynecology organized "Welcome to OBGYN World!" (WOW!) to address a decline in doctors specializing in obstetrics and gynecology, particularly targeting lower-grade medical students.
  • The event was held online to ensure safety during the COVID-19 pandemic and involved participation from 60 of 82 medical schools in Japan, with 285 students and 106 tutors engaged.
  • Post-event feedback revealed that a significant majority of participants (97.6%) developed a strong interest in the specialty, while all tutors acknowledged the event's effectiveness in recruitment, leading to plans for an annual WOW! event.
View Article and Find Full Text PDF

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce the risk of heart failure progression and mortality rates. Moreover, osmotic diuresis induced by SGLT2 inhibition may result in an improved heart failure prognosis. Independent of conventional diuretics in patients with type 2 diabetes (T2D) and chronic heart failure, especially in patients with heart failure with preserved ejection fraction (HFpEF), it is unclear whether SGLT2i chronically reduces estimated plasma volume (ePV).

View Article and Find Full Text PDF
Article Synopsis
  • A conditioning regimen is crucial for allogeneic hematopoietic stem cell transplantation in MDS patients, but determining the best intensity (reduced-intensity vs. myeloablative) can be challenging.
  • This study analyzed 2,567 MDS patients who underwent HCT from 2009 to 2019, creating a machine learning model to calculate a benefit score for reduced-intensity conditioning (RIC).
  • In the validation phase, high-score patients showed improved progression-free survival with RIC compared to myeloablative conditioning (MAC), while low-score patients had worse outcomes with RIC, indicating that machine learning can help personalize treatment plans for MDS.
View Article and Find Full Text PDF